Q-Med U.S. Postmarket Study Needed To Support Deflux Efficacy - Panel Says
This article was originally published in The Gray Sheet
Executive Summary
Q-Med AB should conduct a prospective, randomized, multi-center study in the U.S. of its Deflux injectable gel for vesicoureteral reflux in children as a postmarket condition for FDA approval, FDA's Gastroenterology and Urology Devices Panel recommended.